Sanofi
SNY
482 hedge funds and large institutions have $7.59B invested in Sanofi in 2019 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 170 increasing their positions, 166 reducing their positions, and 49 closing their positions.
111% more call options, than puts
Call options by funds: $48.5M | Put options by funds: $23M
4% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 49
2% more repeat investments, than reductions
Existing positions increased: 170 | Existing positions reduced: 166
0.52% less ownership
Funds ownership: 14.52% → 14.01% (-0.52%)
1% less funds holding
Funds holding: 488 → 482 (-6)
5% less capital invested
Capital invested by funds: $8.02B → $7.59B (-$438M)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$37.6M |
| 2 |
Morgan Stanley
New York
|
+$34M |
| 3 |
Lazard Asset Management
New York
|
+$33.4M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$28.5M |
| 5 |
SCCM
Schafer Cullen Capital Management
New York
|
+$16M |
Top Sellers
SNY Hedge Fund Activity: Q2 2019 in Review
482 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2019, worth a combined $7.59B — down 5.5% from $8.02B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new SNY positions and 49 closed out — a net gain of 2 holders — while 170 added to existing stakes and 166 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $37.6M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $390M.
- 482 institutional investors held Sanofi (SNY) as of Q2 2019, down from 488 in Q1 2019.
- Funds reported $7.59B of Sanofi stock for Q2 2019, down 5.5% quarter-over-quarter.
- 51 funds opened new Sanofi positions in Q2 2019 and 49 closed out, a net change of +2 holders.
- The largest Sanofi buyer in Q2 2019 was Point72 Asset Management, an estimated $37.6M added.
- The largest Sanofi seller in Q2 2019 was Barrow, Hanley, Mewhinney & Strauss, an estimated $390M sold.
Based on aggregated 13F filings for Q2 2019.